Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet

American Journal of Cardiology

Volumn 83, Issue 1, 1999, Pages 43-47

  Cashin Hemphill, Linda ^a   Holmvang, Godtfred ^a   Chan, Raymond C ^a   Pitt, Bertram ^b   Dinsmore, Robert E ^a   Lees, Robert S ^a  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL DIAMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; ISOQUINOLINES; LIPIDS; MALE; MIDDLE AGED; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 0032901697     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00780-2     Document Type: Article

References (20)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
2. Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J. Jr, Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., Klein M., Lamas G.A., Packer M., Rouleau J., Rouleau J.-L., Rutherford J., Wertheimer J.H., Hawkins C.M. The effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677.
3. Yusuf S., Pepine C.J., Garces C., Pouleur H., Salem H., Kostis J., Benedict C., Rousseau M., Bourassa M., Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
4. Aberg G., Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 15:1990;S65-S72.
5. Chobanian A., Haudenschild C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension. 15:1990;327-331.
6. Texter M., Lees R.S., Pitt B., Dinsmore R.E., Uprichard A.C.G. The QUinipril Ischemic Event Trial (QUIET) design and methods evaluation of chronic ACE inhibitor therapy after coronary artery intervention . Cardiovasc Drug Ther. 7:1993;273-282.
7. Lees R.S., Dinsmore R.E. Can ACE inhibition alter the course of coronary heart disease?-Rationale and protocol for QUIET. J Cardiovasc Pharm. 20:(suppl B):1992;S33-S35.
8. Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial. Am J Cardiol. 78:1996;1011-1016.
9. Leung W.H., Sanders W., Alderman E.L. Coronary artery quantitation and data management system for paired cine-angiograms. Cathet Cardiovasc Diagn. 24:1991;121-134.
10. Mantel N., Haentszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
11. Breslow N, Day NE. Statistical Methods in Cancer Research. vol 1: The Analysis of Case-Control Studies. vol 2: The Design and Analysis of Cohort Studies. Lyon: IARC, 1980, 1987.
12. Snedecor G.W., Cochran W.G. Statistical Methods. 1967;Iowa State University Press, Ames, IA.
13. Packer M. Assessment of treatment with lisinopril and survival (ATLAS). Meeting Highlights 47th Annual Scientific Sessions of the American College of Cardiology . Circulation. 97:1998;2380.
14. Rosenson R.S. Myocardial injury the acute phase response and lipoprotein metabolism . J Am Coll Cardiol. 22:1993;933-940.
15. Guazzi M.D., Bussotti M., Grancini L., De Cesare N., Guazzi M., Pera I.L., Loaldi A. Evidence of multifocal activity of coronary disease in patients with acute myocardial infarction. Circulation. 96:1997;1145-1151.
16. Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin . J Am Coll Cardiol. 8:1986;1245-1255.
17. Thompson G.R., Hollyer J., Waters D.D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 6:1995;386-388.
18. Waters D., Higginson L., Gladstone P., Kimball B., May M.L., Boccuzzi S., Lesperance J. Effects of monotherapy with an HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography The Canadian Coronary Atherosclerosis Intervention Trial . Circulation. 89:1995;959-968.
19. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L., Hodis H.N., DeBoer L.W.V., Mahrer P.R., Masteller M.J., Vailas L.I., Alaupvic P., Hirsch L.J. The Monitored Atherosclerosis Regression Study (MARS) coronary angiographic changes with lovastatin therapy . Ann Intern Med. 119:1993;969-976.
20. Blankenhorn D.H., Hodis H.N. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 14:1994;177-192.